Moteur de recherche d’entreprises européennes
Financement de l’UE (3 856 253 €) : L’éducation et la recherche pharmaceutiques avec des liens avec la réglementation : Stratégies novatrices de développement de médicaments et outils réglementaires … Hor 07/03/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
L’éducation et la recherche pharmaceutiques avec des liens avec la réglementation : Stratégies novatrices de développement de médicaments et outils réglementaires adaptés pour faciliter un accès plus rapide aux médicaments
The European Pharma industry is a major contributor to EU well-being, both in public health and economic (sales >200 billion €/year) terms. To maintain global leadership, it must respond to challenges from low-cost producers e.g. China by bringing new drug molecules to market in a streamlined, cost-effective manner. This strategy is underscored by recent initiatives of European regulators to expedite the approval of “breakthrough drugs” so patients can gain earlier access to life-saving drugs. To realise these goals, scientists with an integral understanding of drug development and regulatory approval processes are urgently needed. PEARRL will train 15 Early Stage Researchers (ESR) who can develop new bio-enabling formulations (“better drugs”), biorelevant and in silico methods to predict formulation performance in vivo (“streamlined development”) and serve as communication bridgers between research and regulatory science (“accelerated approval”), thus bringing Pharma and regulatory objectives to fruition. PEARRL brings a multi-sectorial team, comprising key European regulatory authorities, academic leaders in bio-enabling formulations and biopharmaceutics tools, and an array of Pharma companies with a wealth of combined experience in bringing molecules to market, together for the first time to deliver a unique research and training programme. Key PEARRL elements are individual research projects with synergistic output; exposure of all ESR to academia, industry and regulatory in secondments; and ongoing innovative learning via Online Portals, Science Slams and Boot Camps. Key PEARRL impacts will be availability of excellent pharmaceutical researchers; streamlined drug development with a higher success rate for the industrial partners; enriched academic research through cooperation with industry and regulatory; earlier availability of breakthrough medicines to patients; a competitive pharma industry in Europe and contributions to European public health interests.
| Ethniko Kai Kapodistriako Panepistimio Athinon | 484 774 € |
| Fachhochschule Nordwestschweiz FHNW | 530 454 € |
| H. Lundbeck AS | 0,00 € |
| Janssen Pharmaceutica N.V. | 250 560 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 747 649 € |
| Merck KGaA | 249 216 € |
| Pharmaten Anonymos Viomichaniki Kai Emporiki Etaireia Pharmakeftikon Kai Kallyntikon Proionton | 242 387 € |
| Pion INC.(UK) Ltd. | 273 288 € |
| University College Cork - National University of Ireland, Cork | 531 349 € |
| University of Bath | 546 576 € |
https://cordis.europa.eu/project/id/674909
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.